Astragaloside IV-PESV Repressed T Cell Immunosuppression by Inhibiting PD-L1 Expression in Prostate Cancer through STAT3 Pathway

Figure 1

Molecular docking validated astragaloside IV and PESV bound to STAT3 and PD-L1. (a) Molecular docking of the interaction of astragaloside IV with STAT3 and PD-L1. (b) Molecular docking of the interaction of PESV (LPDKVPIR peptide) with STAT3 and PD-L1. (c) Molecular docking of the interaction of PESV (VRDGYIADDK peptide) with STAT3 and PD-L1.

(a)

(b)

(c)